Pharmacological and behavioral profile of ACP-103, a novel 5-HT 2A receptor inverse agonist

The in vitro and in vivo pharmacological properties of ACP-103 [ N -(4-fluorophenylmethyl)- N -(1-methylpiperidin-4-yl)- N’ -(4-(2-methylpropyloxy)phenylmethyl)carbamide (2 R ,3 R )-dihydroxybutanedioate (2:1)] are presented. A potent 5-HT 2A receptor inverse agonist, ACP-103 competitively antagonized the binding of [ 3 H]-ketanserin to heterologously expressed human 5HT 2A receptors with a mean pK i of 9.3 in membranes and 9.70 in whole cells. ACP-103 displayed potent inverse agonist activity in the cell-based functional assay R-SAT, with a mean pIC 50 of 8.7. ACP-103 demonstrated lesser affinity (mean pK i 8.80, membranes, and 8.00, whole cells, as determined by radioligand binding) and potency as an inverse agonist (mean pIC 50 7.1 in R-SAT) at human 5-HT 2C receptors, and lacked affinity and functional activity at 5HT 2B receptors, dopamine D 2 receptors, and other human monoaminergic receptors. Behaviorally, ACP-103 attenuated head twitch behavior (3 mg/kg, p.o.) and prepulse inhibition deficits (1 – 10 mg/kg, s.c.) induced by the 5-HT 2A receptor agonist (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) in rats and reduced the hyperactivity induced in mice by the N -methyl- D -aspartate receptor non-competitive antagonist, MK-801, (0.1 and 0.3 mg/kg, s.c.; 3 mg/kg, p.o.) consistent with a 5-HT 2A receptor mechanism of action in vivo and antipsychotic-like efficacy. ACP-103 demonstrated > 42.6% oral bioavailability in rats. Thus, ACP-103 is a potent,

[1]  C. Halldin,et al.  High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET , 2005, Psychopharmacology.

[2]  H. Meltzer,et al.  Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.

[3]  M. Caron,et al.  RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms* , 2004, Journal of Biological Chemistry.

[4]  U. Hacksell,et al.  Pharmacological Characterization of AC-90179: a Selective 5-HT 2A Receptor Inverse Agonist , 2004 .

[5]  M. Geyer,et al.  Dopaminergic stimulation disrupts sensorimotor gating in the rat , 2004, Psychopharmacology.

[6]  Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. , 2003, Current opinion in investigational drugs.

[7]  M. Stryker,et al.  Sleep and Sleep Homeostasis in Mice Lacking the 5-HT2c Receptor , 2002, Neuropsychopharmacology.

[8]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[9]  M A Geyer,et al.  5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  E. Esposito,et al.  Role of 5-HT(2C) receptors in the control of central dopamine function. , 2001, Trends in pharmacological sciences.

[11]  M. Teitler,et al.  Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[12]  J. Wettstein,et al.  Selectivity of action of typical and atypical antipsychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  A. Carlsson,et al.  The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice , 1999, Journal of Neural Transmission.

[14]  K. Uryu,et al.  Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats , 1997, The Journal of comparative neurology.

[15]  R. Emeson,et al.  Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.

[16]  J. Kehne,et al.  Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. , 1996, The Journal of pharmacology and experimental therapeutics.

[17]  R. Eglen,et al.  The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.

[18]  H. Meltzer,et al.  Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine , 1995 .

[19]  B. Roth,et al.  Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[20]  F. Colpaert,et al.  Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. , 1990, European journal of pharmacology.

[21]  N. Swerdlow,et al.  Startle response models of sensorimotor gating and habituation deficits in schizophrenia , 1990, Brain Research Bulletin.

[22]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[23]  J. Leysen,et al.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. , 1985, Molecular pharmacology.

[24]  W. Freed,et al.  Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice , 1984, Neuropharmacology.

[25]  M. Geyer,et al.  Prestimulus effects on human startle reflex in normals and schizophrenics. , 1978, Psychophysiology.

[26]  J. Leysen,et al.  A serotonergic component of neuroleptic receptors. , 1977, Archives internationales de pharmacodynamie et de therapie.

[27]  S. Snyder,et al.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. , 1976, The American journal of psychiatry.